The green rush could have investors seeing green in pretty much any economic environment.
News & Analysis: GW Pharmaceuticals
GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.
With global CBD sales potentially hitting $22 billion by 2022, here are four CBD stocks you'll want to know about.
Which stock wins in a matchup between these two cannabinoid-focused biotechs?
Which of these two pioneering cannabis plays is the better buy right now?
April's about to shower biopharma investors with important updates that could move these stocks.
Being popular within the investment community doesn't mean being profitable.
Which stock wins in a matchup between a top Canadian marijuana producer and a leading cannabinoid drugmaker?
Popular pot stocks don't always make for the best investments.
To be blunt, these pot stocks are bad news.